XERS Drops 6% in a Day as Earnings Loom and Retail Attention Spikes

XERS heads into its November 5 earnings report with a sharp single-day sell-off, elevated retail attention, and an analyst community that has been steadily raising its view on the stock.

The most striking data point this week is not in the borrow market. It is in retail interest. Wikipedia views and ORTEX page traffic for Xeris Biopharma have produced a z-score of 5.74 against the company's own 90-day history, an unusually large spike in attention for a mid-cap pharma name. That surge in visibility coincided with Friday's 6.1% drop to $10.20, leaving the stock up only 1% on the week after giving back much of its recent gains. The one-month picture still looks constructive, with a 16.8% rise over October, but the single-day move sharpened focus on what comes next.

Positioning in the lending market offers little drama. Short interest runs at roughly 4.3% of free float, down about 13.5% over the past month as some bears covered into the October rally. The borrow itself is about as cheap as it gets, at 0.51% cost to borrow despite a nominal seven-fold jump on the week, the absolute level is still negligible. Availability is effectively unconstrained, with shares to borrow dwarfing the short position by a factor of many multiples. Options traders are equally relaxed. The put/call ratio is 0.13, barely changed from its 20-day average of 0.133 and sitting well below last year's high of 0.50. There is no meaningful defensive hedging ahead of the print.

The Street has been moving in one direction. Barclays raised its target to $14 from $12 on October 6, maintaining Overweight. Leerink Partners lifted to $16 from $12 in September. Both moves followed Barclays' initiation at $9 last December, a pattern of consistent upward revision. The mean analyst target is $12.86, above the current price of $10.20, implying roughly 26% to the target. The bull case rests on Recorlev revenue growth of 131% year-on-year in Q4 2024 and a 123% surge in new prescription starts. Bears flag generic competition risk and R&D execution uncertainty. The EV/EBITDA multiple of 21.7 has eased slightly over the past month, while the PE of 70.8 reflects the early stage of profitability. Forward earnings momentum ranks in the 81st percentile for one-year improvement, one of the stronger factor readings in the snapshot.

Insider selling is worth noting for context, though not for alarm. Three insiders, Pieper, McCulloch and Hecht, sold a combined net $1.59 million worth of shares over the past 90 days. Every transaction was executed under a pre-arranged 10b5-1 plan. Scheduled plan sales are mechanically driven and carry a different signal weight from discretionary open-market decisions. On the institutional side, BlackRock added 1.58 million shares to reach 7.97% of the company as of September 30. State Street added 589,000 shares over the same period. The larger flow was a notable exit: The Vanguard Group filed a 13G/A in March showing its stake had fallen to 0%, down from 6.74%, though a separate Vanguard Capital Management entity filed a fresh 13G in July disclosing a 5.0% stake of 8.64 million shares. Stakes are as last disclosed around the 5% threshold, and holders dropping below that level may exit without a further filing.

The last earnings print, on August 6, produced a 2.2% decline on the day before recovering to a 2.7% gain over the following five sessions. With ten days to the November 5 report, the key questions are whether Recorlev's growth trajectory held through Q3 and how management frames the path to sustained profitability given the still-elevated PE and the modest net loss position heading into the year.